Prusogliptin/Dapagliflozin/Metformin

普卢格列汀/达格列净/二甲双胍

Report date: 2025/12/29 09:31:07

Base Information

Drug NamePrusogliptin/Dapagliflozin/Metformin

Drug Alias NameN/A

ClassificationSmall molecules

Mechanisms of ActionDipeptidyl peptidase IV inhibitorsSodium/glucose cotransporter 2 inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activators

TargetsDipeptidyl peptidase IVSodium/glucose cotransporter 2Protein kinase AMP-activated non-catalytic subunit beta 1

Therapy Area/IndicationsDiabetes Mellitus, Type 2

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsYes Prusogliptin Dapagliflozin Propanediol Monohydrate Metformin Hydrochloride

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesCspc Ouyi Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesCspc Ouyi Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsDiabetes Mellitus, Type 2

Inactive IndicationsN/A

Other Information

ATC CodeN/A